The activation of mTOR signaling, regulated by inactivation mutation of TSC2, is the key point of LAM pathogenesis and the crucial target of rapamycin therapy, which is a hallmark event in LAM treatment. Here, TSC2 is linked to lymphangioleiomyomatosis.